Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Conditions

• Metastatic Hepatocellular Carcinoma
• Solid Tumors
• Solid Tumor, Adult
• FGFR Gene Amplification
• FGFR Gene Alterations
• FGFR3 Gene Alteration
• FGFR3 Gene Mutation
• Advanced Solid Tumors
• FGFR4 Gene Mutation
• FGFR4 Gene Fusions
• FGF19 Gene Amplification
• FGF19 Gene Overexpression
• FGFR3 Gene Fusions
• Locally Advanced Unresectable Hepatocellular Carcinoma

Interventions

• DRUG: TYRA-430

Sponsor

Tyra Biosciences, Inc